Sara Talbot

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

Andrea Herencia-Ropero, Alba Llop‐Guevara, Anna D. Staniszewska et al. · Genome Medicine · 2024 · 62 citations · Full text

Medicine, Oncology, Pharmacology +14

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

Elizabeth Hardaker, Emilio Sanseviero, Ankur Karmokar et al. · Nature Communications · 2024 · 59 citations · Full text

Medicine, Immunology, Pharmacology +17

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

Jordi Bertrán-Alamillo, Ana Giménez‐Capitán, Ruth Román et al. · Molecular Cancer · 2023 · 21 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson et al. · npj Breast Cancer · 2023 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

10x Genomics Gene Expression Flex is a powerful tool for single-cell transcriptomics of xenograft models

Oriol Llorà-Batlle, Anca M. Farcas, Doreth Fransen et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2024 · 13 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14